blog

Before using any clinical AI — a chatbot, a scribe, or an answer tool — the first question is not 'is it accurate?' but 'where does my patient's data go?' A practical guide to the ...

A wave of free, ad-free, citation-backed clinical answer tools has arrived — Heidi Evidence, OpenEvidence in the US, scribes bundling answers into the consultation. The AI 'answer ...

Plenty of doctors already reach for ChatGPT, Claude or Gemini to answer clinical questions — they are fast and conversational. But general-purpose AI is not built for clinical refe...

Clinical AI tools increasingly carry a regulatory class — Class I, Class IIa, sometimes higher — and the number is widely misread as a ranking of quality or safety. It isn't. Class...

Tandem and Tortus are both deployed across the NHS at scale through major distribution partners, and both are climbing the medical-device regulatory ladder. They differ on regulato...

OpenEvidence became the US benchmark for clinical AI search, grounded in peer-reviewed literature. Tandem took the regulated-device route into in-consultation decision support. The...

Both Tandem and Heidi started as AI scribes and have moved into clinical decision support. Their CDS products take different routes on regulation, sourcing and — critically for UK ...

Clinical reference is not new. What AI changes is the interface: instead of searching manually, a clinician can ask a question and review a source-linked answer. The intended use s...

Clinical AI is not one category. Accurx, Heidi, Tortus, Tandem, OpenEvidence and iatroX occupy different layers of the workflow — communication, documentation, coding, decision sup...

National guidance from NICE, CKS and SIGN is necessary but not sufficient — the corridor runs on local referral criteria, local thresholds and pathway quirks. That gap is where cli...

AI scribes are commoditising, and the contested ground in clinical AI is shifting from documentation to the clinical decision itself — a harder, higher-stakes, more heavily regulat...

Tandem has launched clinical decision support as a CE-marked Class IIa medical device — and the bigger story is a 2026 divergence: regulated tools are deepening their UK presence w...